SCHEMBL29967908

SCHEMBL29967908

O=C(O)c1nn[nH]c1Oc1ccc(-c2ccc(-c3cccc(OC(F)F)c3)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DRD1 P21728 2/20 0.50
RXRA P19793 2/20 0.41
RXRB P28702 2/20 0.41
FFAR4 Q5NUL3 2/20 0.38
FFAR1 O14842 1/20 0.38
KCNH2 Q12809 1/20 0.37
MCL1 Q07820 1/20 0.37
THRA P10827 1/20 0.37
THRB P10828 1/20 0.37
HAO2 Q9NYQ3 1/20 0.37
DHODH Q02127 1/20 0.36
PRKAG1 P54619 1/20 0.36
PRKAA1 Q13131 1/20 0.36
PRKAB1 Q9Y478 1/20 0.36
TAS2R14 Q9NYV8 1/20 0.36
MRGPRX4 Q96LA9 1/20 0.36
DAGLA Q9Y4D2 1/20 0.35
HAO1 Q9UJM8 1/20 0.35
PIN1 Q13526 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23319934 1.00 DRD1 (0.50) DRD1RXRARXRBFFAR4FFAR1
SCHEMBL24154489 1.00 DRD1 (0.50) DRD1RXRARXRBFFAR4FFAR1
SCHEMBL25464898 0.91 RXRA (0.40) DRD1RXRARXRBFFAR4FFAR1
SCHEMBL25464983 0.91 RXRA (0.45) DRD1RXRARXRBFFAR4FFAR1
SCHEMBL21312605 0.91 DRD1 (0.43) DRD1PRKAG1PRKAA1PRKAB1MRGPRX4
SCHEMBL24154823 0.91 DRD1 (0.43) DRD1PRKAG1PRKAA1PRKAB1MRGPRX4
SCHEMBL23319901 0.87 MAP4K4 (0.39) DRD1KCNH2THRATHRBMRGPRX4
SCHEMBL21312464 0.87 ALDH1A1 (0.40) DRD1MRGPRX4HAO1
SCHEMBL21296929 0.86 PIN1 (0.49) FFAR4FFAR1MCL1DHODHPRKAG1
SCHEMBL21296859 0.85 HAO1 (0.44) RXRARXRBFFAR4FFAR1DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230143491-A1 TRIAZOLE GLYCOLATE OXIDASE INHIBITORS PHOENIX TISSUE REPAIR, INC. 2023-05-11 US disclosed
US-11401246-B2 Triazole glycolate oxidase inhibitors Cantero Therapeutics, Inc. (US) 2022-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11401246-B2 Triazole glycolate oxidase inhibitors XDH, DUOX1, PNPO DRD1 3113/4885RXRA 3619/4885RXRB 3335/4885
US-20230143491-A1 TRIAZOLE GLYCOLATE OXIDASE INHIBITORS XDH, DUOX1, PNPO DRD1 3113/4885RXRA 3619/4885RXRB 3335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.